Study: Specific mechanism of Cyclocarya paliurus shows promise for treating type 2 diabetes

Type 1 diabetes mellitus and type 2 diabetes mellitus (T2DM) are the two main types of diabetes, while T2DM accounts for 90%-95% of those with diabetes. T2DM is a vital risk factor for cerebral infarction, cardiovascular disease, blindness and kidney failure.

The human gut microbiota plays a fundamental role in the diseases such as obesity and diabetes. Prebiotics are defined as non-digestible food ingredients which could promote selective increase in the growth, numbers, and activity of the microbial genera or species in the gut microbiota.

Traditional Chinese herb medicine had a long history in Asian countries dating from several thousand years ago. One of the most intriguing medicinal plants is Cyclocarya paliurus, which has been used as the drug formulation in traditional Chinese medicine as well as the ingredient in healthy foods and dietary supplements in China.

A recent study conducted an animal trial and examined the structural alterations of the gut microbiota and related metabolites profiles for understanding the specific mechanism of the Cyclocarya paliurus polysaccharide on T2DM.

"To our knowledge, this study is the first direct evidence in vivo by rat model that CP can modulate both the gut microbiota and the metabolites by multi-path to alleviate diabetes." said Prof. Shaoping Nie, the corresponding author for this work.

Cyclocarya paliurus polysaccharide treatment increased the beneficial bacteria genus Ruminococcaceae UCG-005 which was reported to be a key genus for protecting against diabetes.

Although previous studies showed that Cyclocarya paliurus polysaccharide lowered serum glucose and produced beneficial effects on T2DM in murine models, the effects of this polysaccharide on diabetic related gut microbiota, metabolites, inflammation, pancreatic injuries and serum hormones had not been wholly investigated."

Dr. Jielun Hu, Study Co-First Author

Then the amplicon library for the gut microbiota was paired-end sequenced (2 × 250 bp) on an Illumina MiSeq platform, and the UPLC-Triple-TOF/MS analysis of urine samples was carried out according to our established methods.

"In our study, the higher abundance of beneficial bacteria (Ruminococcus) due to CP treatment was involved in the amelioration of type 2 diabetes.

The change of the beneficial bacteria genus Ruminococcaceae UCG-005 was related to expression of Bax and Bcl-2 in pancreas related to inflammation.

Cyclocarya paliurus polysaccharide also could improve 7 metabolism pathways closely with the nutrition metabolisms (amino acids and purine), and energy metabolism (TCA cycle).", said Prof. Shaoping Nie, the corresponding author for this work.

The mechanistic outcome of this study indicated the specific mechanism for using dietary polysaccharides to alleviate type 2 diabetes through multi-path of gut microbiota and host metabolism, and provides important information for the potential use of the Cyclocarya paliurus polysaccharide for prevention or intervention of type 2 diabetes.

Journal reference:

Li, Q., et al. (2020) Hypoglycemic mechanism of polysaccharide from Cyclocarya paliurus leaves in type 2 diabetic rats by gut microbiota and host metabolism alteration.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Mapping Gene Targets of HNF4A and HNF1A in Human Pancreatic Beta Cells and Liver Cells